Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis

Gut Microbes. 2024 Jan-Dec;16(1):2353396. doi: 10.1080/19490976.2024.2353396. Epub 2024 May 22.

Abstract

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that leads to respiratory failure, and eventually death. However, there is a lack of effective treatments for ALS. Here we report the results of fecal microbiota transplantation (FMT) in two patients with late-onset classic ALS with a Japan ALS severity classification of grade 5 who required tracheostomy and mechanical ventilation. In both patients, significant improvements in respiratory function were observed following two rounds of FMT, leading to weaning off mechanical ventilation. Their muscle strength improved, allowing for assisted standing and mobility. Other notable treatment responses included improved swallowing function and reduced muscle fasciculations. Metagenomic and metabolomic analysis revealed an increase in beneficial Bacteroides species (Bacteroides stercoris, Bacteroides uniformis, Bacteroides vulgatus), and Faecalibacterium prausnitzii after FMT, as well as elevated levels of metabolites involved in arginine biosynthesis and decreased levels of metabolites involved in branched-chain amino acid biosynthesis. These findings offer a potential rescue therapy for ALS with respiratory failure and provide new insights into ALS in general.

Keywords: Amyotrophic lateral sclerosis; fecal microbiota transplantation; metagenomic sequencing; non-targeted metabolomics.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amyotrophic Lateral Sclerosis* / microbiology
  • Amyotrophic Lateral Sclerosis* / therapy
  • Bacteroides
  • Faecalibacterium prausnitzii
  • Fecal Microbiota Transplantation*
  • Feces / microbiology
  • Gastrointestinal Microbiome
  • Humans
  • Respiration, Artificial
  • Respiratory Insufficiency* / microbiology
  • Respiratory Insufficiency* / therapy
  • Treatment Outcome

Grants and funding

This research was supported by the Chinese PLA General Hospital under Clinical New Technology Support Project (No. 2022-59).